Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.66 |
| ▸ | PPARG | P37231 | 3/20 | 0.66 |
| ▸ | FABP2 | P12104 | 2/20 | 0.66 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714726 | 0.93 | PPARA (0.61) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL21413784 | 0.90 | PPARA (0.62) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL11712579 | 0.88 | PPARA (0.55) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL22221502 | 0.86 | PPARA (0.58) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL15682174 | 0.85 | PPARA (0.56) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL22221473 | 0.85 | PPARA (0.64) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL11160679 | 0.85 | PPARA (0.56) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL22221670 | 0.84 | PPARA (0.62) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL15682182 | 0.83 | ELANE (0.55) | PPARAPPARGFABP2SLC22A12MAPT | |
| SCHEMBL1584395 | 0.83 | PPARA (0.60) | PPARAPPARGFABP2SLC22A12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | UNIV LOUISIANA STATE (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2020146876-A2 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-4515809-A | ANTICHOLESTEROL | ALFA FARMACEUTICI S.P.A. (IT) | 1985-05-07 | — | — | US | disclosed |
| US-4296125-A | Derivatives of benzoylphenoxyalkanoic acids having normolipemizing activity | ALPHA FARMACEUTICI S.P.A. (IT) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | PPARA 93/4885PPARG 104/4885FABP2 51/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | PPARA 93/4885PPARG 104/4885FABP2 51/4885 |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 | PPARA 1460/4885PPARG 1337/4885FABP2 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.